Sidewinder Therapeutics announced a $137 million Series B financing to advance bispecific ADCs into clinical development.
- Amount
- $137M
- Stage
- Series B
- Announced
- 8 April 2026
- Leads
- Frazier Life Sciences, Novartis Venture Fund
- Other investors
- OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, Alexandria Venture Investments
- Use of funds
- Advance precision bispecific ADCs into clinical development for cancer
- Total raised
- $162M to date
- Checked
- Amount and date checked against the press source